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Abstract
Background: Vitamin D (VitD) deficiency is common in Parkinson’s disease (PD) and has been raised as a possible
PD risk factor. In the past decade, VitD supplementation for potential prevention of age related conditions has
become more common. In this study, we sought to characterize VitD supplementation in early PD and determine
as an exploratory analysis whether baseline characteristics or disease progression differed according to reported
VitD use.
Methods: We analyzed data from the National Institutes of Health Exploratory Trials in Parkinson’s Disease (NET-PD)
Long-term study (LS-1), a longitudinal study of 1741 participants. Subjects were divided into following supplement
groups according to subject exposure (6 months prior to baseline and during the study): no VitD supplement,
multivitamin (MVI), VitD ≥400 IU/day, and VitD + multivitamin (VitD+MVI). Clinical status was followed using the
Unified Parkinson’s Disease Rating Scale, Symbol Digit Modalities Test, total daily levodopa equivalent dose, and
Parkinson’s Disease Questionnaire.
Results: About 5% of subjects took VitD alone, 7% took VitD+MVI, 34% took MVI alone, while 54% took no supplement.
Clinical outcomes at 3 years were similar across all groups.
Conclusion: This study shows VitD supplementation ≥400 IU/day was not common in early PD and that its use was
similar to that seen in the US population. At 3 years, there was no difference in disease progression according to
vitamin D supplement use.
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Background
Numerous reports have shown that vitamin D (VitD) in-
sufficiency is common in aging, is associated with
greater risk of falls and fractures, and that VitD supple-
mentation may reduce the risk of fractures [1]. Because
of this observation, and possibly because of numerous
studies showing associations of D deficiency with dis-
eases in adults, VitD supplementation has become com-
mon. A cross-sectional survey from 2011 to 12 found
that about 21% of adults aged 40–64 and 38% of those >
65 take a separate VitD supplement [2].
A relationship of VitD levels and Parkinson’s disease
(PD) was first recognized in 1997 when Sato and col-
leagues reported a higher prevalence of VitD deficiency
and reduced bone mass in PD [3]. Since then, a number of
studies have confirmed these findings [4] and that a muta-
tion in the VitD receptor is associated with an increased
risk of developing PD [5]. Studies in experimental animal
models of PD have demonstrated neuroprotective effects
of VitD [6], lending support to the hypothesis that VitD
status may influence PD pathogenesis. The Mini-Finland
Health Survey provided additional support of this hypoth-
esis by showing a greater risk for PD in those with lower
VitD levels [7].
Because these studies raise the question as to
whether VitD supplementation affects PD progression,
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we performed a study to characterize contemporary VitD
supplementation in a large, longitudinal cohort of early
PD patients from the National Institutes of Health Ex-
ploratory Trials in Parkinson’s Disease (NET-PD) Long-
term study (LS-1) which enrolled subjects from the
United States and Canada from 2007 to 2010. As a an ex-
ploratory outcome, we also determined whether baseline
characteristics or disease progression outcomes differed
according to reported VitD supplement use prior to base-
line and during the study observation period.
Methods
The NET-PD LS-1 study was a large randomized multi-
center, double-blind, placebo-controlled study of creatine
monohydrate. As previously described, eligible subjects
had diagnosis of PD for < 5 years and had started treat-
ment with levodopa or dopamine agonist for ≥90 days but
< 2 years prior to the baseline visit [8]. Subjects were mon-
itored with annual visits for up to 6 years. The study was
halted before completion after it was determined no dif-
ference would emerge between the treatment arms [8].
At study entry, subjects were required to report all
medications and supplements used in the prior 180 days,
although many provided much longer histories of sup-
plement use. We reviewed the concomitant medication
records for VitD and multivitamin (MVI) use including
supplement brand name (when available), dose, fre-
quency, start date and end date. Of the 1956 records of
supplement use (separate records were created for each
supplement), 620 (31%) documented supplement use
starting prior to 2005. For those taking specified supple-
ments, the published dose was used. The daily dose was
calculated according to dose and frequency. Subjects
were stratified according to the following VitD exposure
groups: no VitD or MVI supplement (NoSupp), multi-
vitamin where dose of VitD was assumed (if not speci-
fied) to be 400 IU/dose (MVI group), ≥ 400 IU/day of
VitD (VitD group), or multivitamin plus ≥ of 400 IU/day
of VitD (VitD+MVI group).
In order to construct defined groups of participants
with different dose and longitudinal VitD exposures,
subjects were included in the analysis if they had been
taking supplements for ≥90 days prior to baseline and
continued that supplement for at least 1.5 years of the
first 3 years of the study or their records indicated no D
supplementation or MVI during this timeframe (NoSupp
group). Subjects who took VitD for shorter durations
during the study period or at lower doses were excluded.
Assessments
Because a significant fraction of subjects did not complete
the 5-year visit due to early study termination, we calcu-
lated mean study outcomes at baseline and the change
from baseline in outcomes at 3 years. Outcomes included
demographics, Unified Parkinson’s Disease Rating Scale
(UPDRS) total score and its subscores obtained in the
practically defined “On-medication” state, [mental (Part
1), activities of daily living (Part 2), and motor (Part 3)],
Parkinson’s Disease Questionnaire (PDQ39), Scales for
Outcomes in Parkinson’s Disease-Cognition (SCOPA--
COG; only performed at baseline and 5 year visit), Symbol
Digit Modalities Test (SDMT), and total daily levodopa
equivalent dose (LED).
Statistical analysis
To investigate baseline characteristics for each group,
means and standard deviations were calculated for con-
tinuous variables, and percentages were computed for
categorical variables. NoSupp, MVI, VitD, VitD+MVI
groups were compared using Analysis of variance
(ANOVA) test for continuous variables, and Chi-square
tests and Fisher’s exact tests for categorical variables.
Baseline age and age at PD diagnosis was summarized
by performing subgroup analyses on males and females,
using ANOVA test within each gender group. Pairwise
comparisons were assessed using the Hochberg’s mul-
tiple testing method. Changes from baseline in the out-
comes were computed at the third year visit, and mean
changes were compared for four groups using ANOVA
test. The ANOVA test was used to compare mean age at
diagnosis for the four supplement groups, within each
age categories. In order to adjust for baseline morbidity,
we also performed the outcome analysis using mixed
models, adjusting for baseline age and the corresponding
baseline score as fixed effects and including site as a ran-
dom effect. SAS 9.4 was used for the analyses.
Results
Of the 1741 subjects who enrolled in the study, 943 sub-
jects had been taking MVI, VitD, or VitD+MVI for
≥90 days prior to baseline and at least 1.5 years of dur-
ation of the study or reported no supplement use
(NoSupp group) during this timeframe. Of these sub-
jects, 54% of subjects took NoSupp, 34% took MVI, 5%
took VitD, and 7% took VitD+MVI (where for VitD, the
dose was > 400 IU/day).
Although disease severity as measured by rating scales
was similar between the groups at baseline, the age at
baseline, and the related age at diagnosis of PD, was
higher in subjects taking supplements [ MVI (60.2 ± 8.7),
VitD (63.9 ± 6.6) and VitD+MVI (64.1 ± 7.7)] compared to
subjects in NoSupp (58.5 ± 9.7) group (Table 1). In order
to address whether supplement use differed according to
age, we then performed an analysis segregated according
to age range (< 50, 50-59, 60–69, ≥70) at PD diagnosis
(Table 2). This analysis confirmed that VitD use was
higher in older patients and that when sorted by age
range, the mean ages at diagnosis were not different. Time
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from diagnosis to start of dopaminergic treatment was not
different in subjects taking supplements (Table 1). The
percentage of females and non-Hispanic whites was higher
in the VitD and VitD+MVI groups.
No differences in mean clinical outcomes were noted
between groups at 3 years (Table 3). An analysis using
mixed models, adjusted for baseline age and correspond-
ing baseline scores as covariates, also failed to show a
difference in outcomes according to supplement use
(Table 4).
Discussion
In this analysis of the NET-PD LS1 cohort, we found
that about 12% of subjects took > 400 IU/day of VitD
supplementation while 34% took a MVI estimated to
contain 400 IU/day of VitD. Disease progression as mea-
sured by a variety of rating scales at 3 years was similar
in all 4 groups. Although methods of ascertainment were
quite different, these rates of MVI and VitD use are in
line with rates reported in the United States population
from the large cross-sectional NHANES study of 34%
for MVI use and 11% for separate VitD supplement use
from 2007 to 8 [2].
Our finding that the age at diagnosis of PD was older
in the MVI group, VitD and VitD plus MVI groups
could suggest a disease delaying effect. However, further
analysis of this data segregated according to age range of
onset showed that VitD supplementation was higher in




MVI D D +MVI P value
(N = 322) (N = 42) (N = 68)
Mean (SD) F test
Age in years 60.1 (9.7) 61.8 (8.6)* 65.3 (6.4)* 65.5 (7.7)* < 0.0001
Age at PD Dx 58.5 (9.7) 60.2 (8.7)* 63.9 (6.6)* 64.1 (7.7)* < 0.0001
Yrs since Dx 1.6 (1.1) 1.7 (1.2) 1.3 (1.0) 1.4 (0.8) 0.07
Years since Dx to D-treatment 1.1 (1.1) 1.3 (1.2) 0.9 (1.0) 1.0 (0.8) 0.08
UPDRS total 25.1 (10.3) 25.4 (10.3) 25.1 (11.4) 24.5 (9.8) 0.92
UPDRS mental 1.2 (1.3) 1.2 (1.3) 1.4 (1.4) 1.2 (1.3) 0.85
UPDRS ADL 6.8 (3.7) 6.8 (3.6) 6.2 (3.9) 6.4 (3.4) 0.66
PDQ 39 summary 12.9 (10.4) 11.5 (8.7) 12.5 (9.6) 10.5 (8.3) 0.08
SCOPA COG 30.4 (5.1) 30.4 (5.2) 30.9 (4.6) 31.1 (5.0) 0.71
SDMT 45.1 (11.1) 44.4 (10.9) 45.2 (11.4) 45.9 (11.4) 0.71
Total daily LED 374.9 (224.9) 371.3 (232.8) 390.0 (208.0) 367.4 (355.4) 0.96
Frequency (%) X2testa
Female % 144 (28.2%) 94 (29.2%) 27 (64.3%) 38 (55.9%) < 0.0001
Non-Hispanic white 448 (87.7%) 303 (94.1%) 41 (97.6%) 66 (97.1%) 0.001
Education > 17 yearsa 149 (29.2%) 118 (36.7%) 16 (38.1%) 18 (26.5%) 0.08
Abbreviations: PD Parkinson’s disease, Dx diagnosis, yrs years, D-treatment dopaminergic treatment (dopamine agonist or levodopa), UPDRS Unified Parkinson’s
Disease Rating Scale, ADL activities of daily living, PDQ Parkinson’s disease questionnaire, SCOPA COG Scales for outcomes of Parkinson’s disease-Cognition, SDMT
symbol digit modalities test, LED levodopa equivalent dose
*p < .05 compared to NoSupp, according to pairwise comparisons Hochberg method
aX2 test was calculated by Fisher’s exact test
Table 2 Analysis of Supplement Use by Age Range
Age at Diagnosis Statistics No Supp (N = 511) MVI (N = 322) VitD (N = 42) VitD +MVI (N = 68) p-value
< 50 Freq (%) 91 (70%) 35 (27%) 1 (1%) 2 (2%)
Mean (SD) 44.04 (4.54) 44.63 (5.07) 45.00 (NA) 46.50 (3.54) 0.83
50–59 Freq (%) 182 (58%) 106 (34%) 10 (3%) 17 (5%)
Mean (SD) 54.85 (2.73) 54.87 (2.96) 56.70 (3.09) 56.06 (2.88) 0.08
60–69 Freq (%) 164 (46%) 139 (39%) 23 (6%) 30 (9%)
Mean (SD) 63.81 (2.90) 64.12 (2.85) 64.83 (3.16) 64.13 (2.76) 0.42
≥70 Freq (%) 74 (52%) 42 (29%) 8 (6%) 19 (13%)
Mean (SD) 73.54 (3.21) 73.29 (2.62) 72.38 (1.06) 73.37 (3.92) 0.78
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older participants (suggesting reverse causation), and
that mean age at diagnosis was no longer significantly
different between groups.
Our finding that VitD supplementation did not affect
PD progression is consistent with observations from the
DATATOP study of early PD in which no correlation was
seen between VitD levels and disease progression [9].
However, a more recent 3-year study did find a small, but
significant association between VitD levels measured at
baseline and motor progression [10], raising the possibility
that the amount of VitD supplementation by the NET-PD
LS1 participants was inadequate to provide benefit.
Although there is evidence of high prevalence of VitD
deficiency in early PD [9] and established PD [11], there
is currently little published regarding the effect of VitD
supplementation in PD. Suzuki et al. conducted a ran-
domized, placebo-controlled study examining the effect
supplementation with 1200 IU/day of vitamin D3/d for
12 months [12]. They found that D supplementation was
associated with smaller changes in a number of out-
comes measures including the Hoehn and Yahr stage,
UPDRS part II and total, and some domains of the
PDQ39 as well as the participants' VitD receptor geno-
type. Their study differed from our study in a number of
ways since it was randomized, larger doses of VitD were
specified, and because subjects started treatment after
baseline while our study followed subjects on established
VitD supplementation for a longer duration of time.
Their design examines both potential treatment and
neuroprotective effects of D supplementation while our
study more specifically examined baseline characteristics
of supplemented patients and their progression.
Our study has several limitations. As it is a secondary
analysis, subjects were not randomized to treatment.
Also, subjects were analyzed according to reported sup-
plement dose with no independent measurements of
serum VitD levels nor were we able to account for dif-
fering levels of sunlight exposure. Moreover although
many subjects provided information regarding supple-
ment use for years prior to study entry, study procedures
only required report of supplement use in the 180 days
prior to baseline, which for the majority of subjects was
after their PD diagnosis. There were also lower numbers
of subjects taking VitD or VitD+MVI compared to the
other groups. Finally, while this study did not show dif-
ferences in disease progression in the first three years
Table 3 Mean Change in Outcomes and at 3-year Visit
No D Supplement (N = 511) MVI (N = 322) D (N = 42) D +MVI (N = 68) P value
Mean (SD) F test
Change in UPDRS total 5.5 (11.8) 6.2 (12.0) 4.9 (9.8) 9.2 (14.3) 0.12
Change in UPDRS mental 0.5 (1.5) 0.5 (1.5) 0.6 (2.0) 0.6 (1.8) 0.83
Change in UPDRS ADL 2.0 (4.4) 2.3 (4.5) 1.9 (3.6) 3.0 (4.7) 0.30
Change in PDQ 39 summary 4.6 (10.4) 4.3 (9.6) 4.0 (11.3) 4.8 (10.5) 0.96
Change in SDMT 0.002 (9.5) −0.2 (9.4) −1.6 (11.0) −0.8 (13.3) 0.73
Change in Total daily LED 294.6 (367.1) 268.4 (339.8) 220.6 (244.5) 271.5 (346.4) 0.48
Abbreviations: UPDRS Unified Parkinson’s Disease Rating Scale, ADL activities of daily living, PDQ Parkinson’s disease questionnaire, SDMT symbol digit modalities
test, LED levodopa equivalent dose
Table 4 Change in Outcomes at 3-year Visit according to mixed
modelsa
Outcome Group Estimate P value
Change in UPDRS total No Supplement . .
MVI 0.248 0.77
D −1.517 0.43
D +MVI 2.540 0.10
Change in UPDRS ADL No Supplement . .
MVI 0.117 0.70
D −0.555 0.43
D +MVI 0.469 0.41
Change in UPDRS mental No Supplement . .
MVI −0.058 0.58
D 0.083 0.73
D +MVI 0.083 0.67
Change in PDQ39 No Supplement . .
MVI −0.571 0.43
D − 0.986 0.55
D +MVI −0.422 0.75
Change in SDMT No Supplement . .
MVI −0.041 0.95
D −0.654 0.67
D +MVI 0.871 0.48
Change in Total daily LED No Supplement . .
MVI −23.174 0.34
D −63.506 0.25
D +MVI −19.346 0.66
Abbreviations: UPDRS Unified Parkinson’s Disease Rating Scale, ADL activities of
daily living, PDQ Parkinson’s disease questionnaire, SDMT symbol digit
modalities test, LED levodopa equivalent dose
aModel controlled for baseline age and the corresponding baseline score as
fixed effects and including site as a random effect
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after starting dopaminergic treatment, it is possible that
D supplementation could affect later PD progression.
Conclusion
Although VitD insufficiency is common in PD, this study
shows VitD > 400 IU/day supplementation was not com-
mon and was similar to the rate observed in cross-sectional
studies of the general US population according to age
group. Although no difference in early disease progression
was observed in patients taking VitD supplementation, it
remains possible that consistent VitD supplementation
could reduce the development of disability related to bone
health, since osteoporosis is more common in PD and the
risk of falls and bone fracture increase with disease dur-
ation. These data may be helpful in the design of studies
testing the effect of vitamin D supplementation over a lon-
ger time frame.
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